Skip to content
Open access

Safety and effectiveness of efgartigimod in patients with generalized myasthenia gravis by autoantibody subtype: analysis of post-marketing surveillance in Japan

Aug 2026 · Scientific Reports · 0 citations

Abstract

Efgartigimod for intravenous infusion (efgartigimod-IV) is approved in Japan for generalized myasthenia gravis (gMG) regardless of autoantibody subtypes, whereas the approvals in other countries are restricted to only anti-acetylcholine receptor antibody (AChR-Ab) positive. Post-marketing surveillance was conducted in Japan with gMG patients who received efgartigimod-IV from 2022 to 2023. Safety analysis set included 473 patients: 56.7% ( n  = 268) AChR-Ab positive, 13.3% ( n  = 63) anti-muscle-specific kinase antibody (MuSK-Ab) positive, 29.2% ( n  = 138) double-seronegative (AChR-Ab and MuSK-Ab negative), and 0.85% ( n  = 4) unavailable. Adverse drug reactions and serious adverse drug reactions were reported in 22.6% and 4.2% of patients. No specific safety signals were observed in any of the autoantibody subtypes. Effectiveness analysis set consisted of 307 patients. After three weeks from the first administration, mean Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score decreased from 7.2 to 4.2: − 3.0 points (standard deviation [SD]: 3.0, p  < 0.001). At one-year, mean dose (SD) (mg/day) of oral glucocorticoid decreased from 10.7 to 7.7: − 3.0 mg/day (SD: 6.2, p  < 0.001). Similar results were observed across all autoantibody subtypes. In real-world settings, our results demonstrated that efgartigimod-IV was well tolerated and effective in patients with gMG regardless of autoantibody subtypes. Glucocorticoid dosage reduction was observed following efgartigimod initiation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.